You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 13, Issue 11

June-1 2021 - 344 articles

Cover Story: Tumor progression, therapy resistance and metastasis are profoundly controlled by the tumor microenvironment. Endothelial cell contribution to tumor progression was initially only attributed to the formation of new blood vessels (angiogenesis). However, endothelial cells do not only provide conduits for blood transportation but also express numerous membrane-bound and secreted factors. Such angiocrine functions promote aggressiveness of cancer cells, influence the immune response towards cancer cells and thereby contribute to tumor progression and metastasis. Crosstalk between endothelial cells and cancer cells contributes to the cancer stem cell phenotype, epithelial to mesenchymal transition, immunosuppression, remodeling of the extracellular matrix and intravasation of cancer cells into the bloodstream in primary tumor but also at the pre-metastatic niche and metastasis. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (344)

  • Article
  • Open Access
2 Citations
2,578 Views
11 Pages

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities

  • Michala Skovlund Sørensen,
  • Thomas Colding-Rasmussen,
  • Peter Frederik Horstmann,
  • Klaus Hindsø,
  • Christian Dehlendorff,
  • Julia Sidenius Johansen and
  • Michael Mørk Petersen

7 June 2021

Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evalua...

  • Article
  • Open Access
15 Citations
5,131 Views
15 Pages

Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential

  • Charles S. Fermaintt,
  • Thilini Peramuna,
  • Shengxin Cai,
  • Leila Takahashi-Ruiz,
  • Jacob Nathaniel Essif,
  • Corena V. Grant,
  • Barry R. O’Keefe,
  • Susan L. Mooberry,
  • Robert H. Cichewicz and
  • April L. Risinger

7 June 2021

The heterogeneity of triple negative breast cancer (TNBC) has led to efforts to further subtype this disease with the hope of identifying new molecular liabilities and drug targets. Furthermore, the finding that TNBC is the most inherently immunogeni...

  • Review
  • Open Access
54 Citations
12,673 Views
28 Pages

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

  • Marco Ferrari,
  • Stefano Taboni,
  • Andrea Luigi Camillo Carobbio,
  • Enzo Emanuelli,
  • Roberto Maroldi,
  • Paolo Bossi and
  • Piero Nicolai

7 June 2021

Sinonasal squamous cell carcinoma is a rare tumor affecting the nasal cavity and paranasal sinuses. Several aspects of this disease, ranging from epidemiology to biology, pathology, diagnosis, staging, treatment, and post-treatment surveillance are c...

  • Review
  • Open Access
3 Citations
3,651 Views
15 Pages

7 June 2021

Due to the limited effectiveness of immunotherapy used as first-line monotherapy in patients with non-small-cell lung cancer (NSCLC), the concepts of combining classical immunotherapy based on immune checkpoint antibodies with other treatment methods...

  • Review
  • Open Access
47 Citations
7,607 Views
20 Pages

Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies

  • Zachary L. Taylor,
  • Jesper Vang,
  • Elixabet Lopez-Lopez,
  • Natanja Oosterom,
  • Torben Mikkelsen and
  • Laura B. Ramsey

7 June 2021

Methotrexate (MTX) is a mainstay therapeutic agent administered at high doses for the treatment of pediatric and adult malignancies, such as acute lymphoblastic leukemia, osteosarcoma, and lymphoma. Despite the vast evidence for clinical efficacy, hi...

  • Article
  • Open Access
4 Citations
3,808 Views
19 Pages

A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways

  • Dana M. Zaher,
  • Wafaa S. Ramadan,
  • Raafat El-Awady,
  • Hany A. Omar,
  • Fatema Hersi,
  • Vunnam Srinivasulu,
  • Ibrahim Y. Hachim,
  • Farah I. Al-Marzooq,
  • Cijo G. Vazhappilly and
  • Salim Merali
  • + 5 authors

7 June 2021

(1) Background: Today, the discovery of novel anticancer agents with multitarget effects and high safety margins represents a high challenge. Drug discovery efforts indicated that benzopyrane scaffolds possess a wide range of pharmacological activiti...

  • Study Protocol
  • Open Access
47 Citations
5,595 Views
15 Pages

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

  • Alessandra Raimondi,
  • Federica Palermo,
  • Michele Prisciandaro,
  • Massimo Aglietta,
  • Lorenzo Antonuzzo,
  • Giuseppe Aprile,
  • Rossana Berardi,
  • Giovanni G. Cardellino,
  • Giovanni De Manzoni and
  • Ferdinando De Vita
  • + 22 authors

7 June 2021

In resectable gastric or gastroesophageal junction cancer (GC/GEJC), the powerful positive prognostic effect and the potential predictive value for a lack of benefit from the combination of adjuvant/peri-operative chemotherapy for the MSI-high status...

  • Feature Paper
  • Review
  • Open Access
7 Citations
5,094 Views
18 Pages

Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction

  • Andrew F. Berdel,
  • Christian Schwöppe,
  • Caroline Brand,
  • Saliha Harrach,
  • Kathrin Brömmel,
  • Heike Hintelmann,
  • Georg Lenz,
  • Ruediger Liersch,
  • Hauke Heinzow and
  • Christoph Schliemann
  • + 3 authors

7 June 2021

Besides its central functional role in coagulation, TF has been described as being operational in the development of malignancies and is currently being studied as a possible therapeutic tool against cancer. One of the avenues being explored is retar...

  • Article
  • Open Access
4 Citations
3,767 Views
19 Pages

Elevated Expression of the RAGE Variant-V in SCLC Mitigates the Effect of Chemotherapeutic Drugs

  • Bindhu K. Madhavan,
  • Zhe Han,
  • Bishal Singh,
  • Nico Bordt,
  • Serap Kaymak,
  • Obul Reddy Bandapalli,
  • Lars Kihm,
  • Khurrum Shahzad,
  • Berend Isermann and
  • Stephan Herzig
  • + 2 authors

7 June 2021

Small cell lung carcinoma (SCLC) is a highly aggressive malignancy with a very high mortality rate. A prominent part of this is because these carcinomas are refractory to chemotherapies, such as etoposide or cisplatin, making effective treatment almo...

  • Article
  • Open Access
12 Citations
3,836 Views
16 Pages

Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada

  • Christopher J. D. Wallis,
  • Bobby Shayegan,
  • Scott C. Morgan,
  • Robert J. Hamilton,
  • Ilias Cagiannos,
  • Naveen S. Basappa,
  • Cristiano Ferrario,
  • Geoffrey T. Gotto,
  • Ricardo Fernandes and
  • Soumyajit Roy
  • + 8 authors

7 June 2021

De novo cases of metastatic prostate cancer (mCSPC) are associated with poorer prognosis. To assist in clinical decision-making, we aimed to determine the prognostic utility of commonly available laboratory-based markers with overall survival (OS). I...

of 35

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694Creative Common CC BY license